AKT1 and cancer: ERBB2 gene mutation could deteriorate the process of cancer, which involves tumor inflammation signature, cellular response to hypoxia, tumor proliferation signature, EMT marker, angiogenesis, apoptosis, DNA repair, G2M checkpoint, inflammatory response, PI3K/AKT/mTOR pathway, p53 pathway, MYC target, TGFB, IL-10 anti-inflammation signature pathway, ROS upregulated genes, DNA replication, collagen formation, degradation of ECM, and ferroptosis pathways.